A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
Study sponsor: AnaptysBio, Inc. · ANAB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-11-29Estimated
Enrollment · participants420Estimated
Source updated2024-11-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.